| 马洁云,王建红,张一心.CYP3A5基因多态性与晚期非小细胞肺癌紫杉醇化疗敏感性关系的研究[J].中国肿瘤,2014,23(10):869-872. |
| CYP3A5基因多态性与晚期非小细胞肺癌紫杉醇化疗敏感性关系的研究 |
| The Relationship between CYP3A5 Gene Polymorphisms and Sensitivity to Paclitaxel-based Chemotherapy in Advanced Non-small Cell Lung Cancer |
| 投稿时间：2014-04-12 |
| DOI：10.11735/j.issn.1004-0242.2014.10.A017 |
|
 |
| 中文关键词: CYP3A5 基因多态性 紫杉醇 非小细胞肺癌 化疗敏感性 |
| 英文关键词:CYP3A5 gene polymorphism paclitaxel non-small cell lung cancer chemosensitivity |
| 基金项目: |
|
| 摘要点击次数: 2221 |
| 全文下载次数: 915 |
| 中文摘要: |
| 摘 要：［目的］ 探讨CYP3A5基因多态性与晚期非小细胞肺癌紫杉醇化疗敏感性的关系。［方法］ 对接受以紫杉醇为基础化疗方案进行化疗的60例晚期非小细胞肺癌患者，采用PCR-RFLP方法检测外周血CYP3A5 *1/*3基因多态性，比较不同基因型之间紫杉醇化疗近期疗效的差异。［结果］ 60例患者中，CYP3A5基因为 *1/*1、*1/*3和 *3/*3型的患者数分别有6例(10.00%)、20例(33.33%)和34例(56.67%)。*1/*1和*1/*3基因型患者的有效率为19.23%，*3/*3基因型患者的有效率为55.88%，*1/*1和*1/*3基因型患者的有效率明显低于*3/*3基因型患者（P=0.004）。［结论］ 对非小细胞肺癌患者治疗前进行CYP3A5基因型的测定，可预测紫杉醇的化疗疗效。 |
| 英文摘要: |
| Abstract：［Purpose］ To investigate the relationship between CYP3A5 gene polymorphisms and sensitivity to paclitaxel-based chemotherapy in patients with advanced non-small cell lung cancer(NSCLC).［Methods］ Sixty cases with advanced NSCLC undergoing paclitaxel-based chemotherapy were enrolled. CYP3A5 genotypes were determined by PCR-RFLP，and the short term response was compared in patients with different CYP3A5 genotypes. ［Results］ The *1/*1，*1/*3 and *3/*3 genotypes were presented in 6 patients(10.00%)，20 patients(33.33%) and 34 patients(56.67%)，respectively. The response to paclitaxel-based chemotherapy was 19.23% in patients with CYP3A5 *1/*1 and *1/*3，and 55.88% in patients with CYP3A5 *3/*3. Patients with CYP3A5 *3/*3 genetype had a higher response than that with CYP3A5 *1/*1 and *1/*3(P=0.04). ［Conclusion］ CYP3A5 may be as an indicator for sensitivity to paclitaxel-based chemotherapy in patients with advanced non-small cell lung cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |